PDF(Pubmed)
Abstract：
UNASSIGNED: Mesenchymal-epithelial transition (MET) amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence in situ hybridization (FISH) is the gold standard for MET amplification detection. However, it is inapplicable when tissue samples are unavailable.
UNASSIGNED: This study assessed the performance of plasma droplet digital polymerase chain reaction (ddPCR) in MET amplification detection in NSCLC patients.
UNASSIGNED: A total of 87 NSCLC patients were enrolled, and 94 paired tissue and plasma samples were analyzed for the concordance between FISH and plasma ddPCR/tissue next-generation sequencing (NGS) in detecting MET amplification. In addition, the efficacy of patients with MET amplification using different detection methods who were treated with MET-TKIs was evaluated.
UNASSIGNED: Plasma ddPCR showed substantial concordance with FISH (74.1% sensitivity, 92.5% specificity, and 87.2% accuracy with a kappa value of 0.68) and outperformed tissue NGS (kappa value of 0.64) in MET amplification detection. Combined plasma ddPCR and tissue NGS showed substantial concordance with FISH (92.3% sensitivity, 89.2% specificity, and an accuracy of 90.1% with a kappa value of 0.77). The efficacy is comparable in these NSCLC patients with MET amplification detected by FISH and plasma ddPCR who were treated with MET-TKIs.
UNASSIGNED: Plasma ddPCR is a potentially reliable method for detecting MET amplification in advanced NSCLC patients. Combined plasma ddPCR and tissue NGS might be an alternative or complementary method to MET amplification detection.
UNASSIGNED: This study assessed the performance of plasma droplet digital polymerase chain reaction (ddPCR) in MET amplification detection in NSCLC patients.
UNASSIGNED: A total of 87 NSCLC patients were enrolled, and 94 paired tissue and plasma samples were analyzed for the concordance between FISH and plasma ddPCR/tissue next-generation sequencing (NGS) in detecting MET amplification. In addition, the efficacy of patients with MET amplification using different detection methods who were treated with MET-TKIs was evaluated.
UNASSIGNED: Plasma ddPCR showed substantial concordance with FISH (74.1% sensitivity, 92.5% specificity, and 87.2% accuracy with a kappa value of 0.68) and outperformed tissue NGS (kappa value of 0.64) in MET amplification detection. Combined plasma ddPCR and tissue NGS showed substantial concordance with FISH (92.3% sensitivity, 89.2% specificity, and an accuracy of 90.1% with a kappa value of 0.77). The efficacy is comparable in these NSCLC patients with MET amplification detected by FISH and plasma ddPCR who were treated with MET-TKIs.
UNASSIGNED: Plasma ddPCR is a potentially reliable method for detecting MET amplification in advanced NSCLC patients. Combined plasma ddPCR and tissue NGS might be an alternative or complementary method to MET amplification detection.
摘要：
■间充质-上皮转化（MET）扩增是非小细胞肺癌（NSCLC）的重要致癌驱动因素和表皮生长因子受体酪氨酸激酶抑制剂（TKIs）的耐药机制。荧光原位杂交(FISH)是MET扩增检测的金标准。然而,当组织样本不可用时，它是不适用的。
■这项研究评估了血浆液滴数字聚合酶链反应（ddPCR）在NSCLC患者MET扩增检测中的性能。
■共纳入87例NSCLC患者，分析了94份配对组织和血浆样本的FISH与血浆ddPCR/组织下一代测序(NGS)检测MET扩增的一致性.此外,对使用MET-TKIs治疗的使用不同检测方法进行MET扩增的患者的疗效进行了评价.
■血浆ddPCR显示与FISH基本一致（灵敏度为74.1%，92.5%特异性，和87.2%的准确度，kappa值为0.68），在MET扩增检测中优于组织NGS（kappa值为0.64）。联合血浆ddPCR和组织NGS显示与FISH基本一致(灵敏度为92.3%,89.2%的特异性，精度为90.1%，kappa值为0.77)。在用MET-TKIs治疗的这些具有通过FISH和血浆ddPCR检测的MET扩增的NSCLC患者中,功效是相当的。
■血浆ddPCR是检测晚期NSCLC患者MET扩增的潜在可靠方法。组合的血浆ddPCR和组织NGS可能是MET扩增检测的替代或补充方法。
■这项研究评估了血浆液滴数字聚合酶链反应（ddPCR）在NSCLC患者MET扩增检测中的性能。
■共纳入87例NSCLC患者，分析了94份配对组织和血浆样本的FISH与血浆ddPCR/组织下一代测序(NGS)检测MET扩增的一致性.此外,对使用MET-TKIs治疗的使用不同检测方法进行MET扩增的患者的疗效进行了评价.
■血浆ddPCR显示与FISH基本一致（灵敏度为74.1%，92.5%特异性，和87.2%的准确度，kappa值为0.68），在MET扩增检测中优于组织NGS（kappa值为0.64）。联合血浆ddPCR和组织NGS显示与FISH基本一致(灵敏度为92.3%,89.2%的特异性，精度为90.1%，kappa值为0.77)。在用MET-TKIs治疗的这些具有通过FISH和血浆ddPCR检测的MET扩增的NSCLC患者中,功效是相当的。
■血浆ddPCR是检测晚期NSCLC患者MET扩增的潜在可靠方法。组合的血浆ddPCR和组织NGS可能是MET扩增检测的替代或补充方法。
